person · Reporting owner

Metzger Michael A

Disclosed activity across 3 companies

Tapewire entity: 31181
SEC CIK: 0001507220

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Pyxis Oncology, Inc.PYXS · Entity 5986	Director	March 24, 2026	March 25, 2026
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director · Chief Executive Officer	July 08, 2026	July 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pyxis Oncology, Inc.

Report date March 24, 2026 · Filed March 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24	Direct	45,867	Reported balance After 2026-03-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Syndax Pharmaceuticals Inc

Report date July 08, 2026 · Filed July 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	484,843	Ending reported balance After 2026-07-08 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-07-08 · Exercise / conversion · Acquired 32,375 · Balance 517,218 Row 2 · 2026-07-08 · Sale · Disposed 32,375 · Balance 484,843 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested. F2: The sale prices ranged from $24.00 to $24.43
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2029-02-06	Direct	0	Reported balance After 2026-07-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-08 · Exercise / conversion · Acquired 32,375 · Balance 0 F3: This option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested.

F2: The sale prices ranged from $24.00 to $24.43

F3: This option is fully vested.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CTI BIOPHARMA CORP

Report date June 26, 2023 · Filed June 26, 2023

Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25	Direct	Reported balance After 2023-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-26 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61	Direct	Reported balance After 2023-06-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-26 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00	Direct	Reported balance After 2023-06-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-26 · Disposition to issuer · Disposed 63,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30	Direct	Reported balance After 2023-06-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49	Direct	Reported balance After 2023-06-26 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08	Direct	Reported balance After 2023-06-26 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)

F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 08, 2026 Filed Jul 9, 2026 20:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Option (Right to buy) · Derivative	32,375	$0.00 Strike: $6.38	$0.00	Disclosure SEC source: 0001193125-26-299803 · ownership.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,375 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
July 08, 2026 Filed Jul 9, 2026 20:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	32,375	$24.24	$784,776.48	Disclosure SEC source: 0001193125-26-299803 · ownership.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,843 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $24.00 to $24.43 Read SEC document
July 08, 2026 Filed Jul 9, 2026 20:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	32,375	$6.38	$206,552.50	Disclosure SEC source: 0001193125-26-299803 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 517,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:30 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	6,847	$18.99	$130,024.53	Disclosure SEC source: 0001193125-26-253601 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,843 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 24, 2026 Filed Mar 25, 2026 21:09 UTC	Pyxis Oncology, Inc. PYXS · Entity 5986	GrantStock Option (Right to Buy) · Derivative	45,867	$0.00 Strike: $1.36	$0.00	Disclosure SEC source: 0001193125-26-124342 · ownership.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 45,867 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
February 09, 2026 Filed Feb 10, 2026 14:00 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	17,159	$21.03	$360,819.45	Disclosure SEC source: 0001193125-26-043814 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,690 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
February 06, 2026 Filed Feb 6, 2026 22:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	7,412	$20.62	$152,835.44	Disclosure SEC source: 0001193125-26-041500 · ownership.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,849 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Options (Right to buy) · Derivative	440,000	$20.43 Strike: $20.43	$8,989,200.00	Disclosure SEC source: 0001193125-26-041500 · ownership.xml · derivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2036-02-04 F4 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	144,600	$0.00	$0.00	Disclosure SEC source: 0001193125-26-041500 · ownership.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,261 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	73,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-041500 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,661 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document
September 08, 2025 Filed Sep 8, 2025 22:45 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock options (Right to buy) · Derivative	157,307	$0.00 Strike: $10.90	$0.00	Disclosure SEC source: 0000950170-25-113659 · ownership.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,307 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
September 08, 2025 Filed Sep 8, 2025 22:45 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	157,307	$16.41	$2,582,021.37	Disclosure SEC source: 0000950170-25-113659 · ownership.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 298,661 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,319,634 options to purchase shares of common stock that are vested and immediately exercisable and a total of 651,241 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $16.21 to $17.06. Read SEC document
September 08, 2025 Filed Sep 8, 2025 22:45 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	157,307	$10.90	$1,714,646.30	Disclosure SEC source: 0000950170-25-113659 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 16, 2025 Filed Jul 18, 2025 20:30 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	7,534	$9.29	$69,953.19	Disclosure SEC source: 0000950170-25-096947 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,661 F1 · price: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 31, 2025 Filed Apr 2, 2025 13:05 UTC	Pyxis Oncology, Inc. PYXS · Entity 5986	GrantStock Option (Right to Buy) · Derivative	36,979	$0.98 Strike: $0.98	$36,239.42	Disclosure SEC source: 0000950170-25-048903 · ownership.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
March 14, 2025 Filed Mar 17, 2025 10:01 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock options (Right to buy) · Derivative	6,074	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0000950170-25-039787 · ownership.xml · derivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,074 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document
March 14, 2025 Filed Mar 17, 2025 10:01 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	6,074	$7.20	$43,732.80	Disclosure SEC source: 0000950170-25-039787 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock options (Right to buy) · Derivative	7,814	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0000950170-25-034634 · ownership.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,814 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	7,814	$15.05	$117,563.97	Disclosure SEC source: 0000950170-25-034634 · ownership.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,121 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,321,245 options to purchase shares of common stock that are vested and immediately exercisable and a total of 805,428 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $15.00 to $15.27 Read SEC document
March 04, 2025 Filed Mar 6, 2025 21:10 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	7,814	$7.20	$56,260.80	Disclosure SEC source: 0000950170-25-034634 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:15 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	13,288	$15.50	$206,017.15	Disclosure SEC source: 0000950170-25-019000 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,121 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:42 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Options (Right to buy) · Derivative	364,000	$14.65 Strike: $14.65	$5,332,600.00	Disclosure SEC source: 0000950170-25-016384 · ownership.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,000 Underlying: Common Stock · 364,000 shares Expires 2035-02-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:42 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	89,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-016384 · ownership.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,409 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:42 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	60,500	$0.00	$0.00	Disclosure SEC source: 0000950170-25-016384 · ownership.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,409 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document
June 10, 2024 Filed Jun 10, 2024 21:31 UTC	Pyxis Oncology, Inc. PYXS · Entity 5986	GrantStock Option (Right to Buy) · Derivative	70,683	$0.00 Strike: $3.97	$0.00	Disclosure SEC source: 0000950170-24-071438 · ownership.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,683 Underlying: Common Stock · 70,683 shares Expires 2034-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest in three equal annual installments beginning on the first anniversary of June 10, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Options (Right to buy) · Derivative	214,500	$22.28 Strike: $22.28	$4,779,060.00	Disclosure SEC source: 0001562180-24-001223 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,500 Underlying: Common Stock · 214,500 shares Expires 2034-02-07 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	39,000	$0.00	$0.00	Disclosure SEC source: 0001562180-24-001223 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,909 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document
February 07, 2024 Filed Feb 9, 2024 21:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	107,250	$0.00	$0.00	Disclosure SEC source: 0001562180-24-001223 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,909 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	80,000	Not disclosed Strike: $4.08	Not disclosed	Disclosure SEC source: 0000899243-23-016486 · doc4.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	80,000	Not disclosed Strike: $4.49	Not disclosed	Disclosure SEC source: 0000899243-23-016486 · doc4.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	80,000	Not disclosed Strike: $3.30	Not disclosed	Disclosure SEC source: 0000899243-23-016486 · doc4.xml · derivative · entry 4 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	63,000	Not disclosed Strike: $1.00	Not disclosed	Disclosure SEC source: 0000899243-23-016486 · doc4.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	60,000	Not disclosed Strike: $4.61	Not disclosed	Disclosure SEC source: 0000899243-23-016486 · doc4.xml · derivative · entry 2 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	Not disclosed Strike: $4.25	Not disclosed	Disclosure SEC source: 0000899243-23-016486 · doc4.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
April 05, 2023 Filed Apr 7, 2023 18:22 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	GrantStock Option (right to buy) · Derivative	80,000	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0000899243-23-010983 · doc4.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-04-05 F1 · derivative.exercise_date: This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2024 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document
February 06, 2023 Filed Feb 8, 2023 21:49 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	5,959	$27.64 Strike: $6.38	$164,697.23	Disclosure SEC source: 0001562180-23-001118 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,959 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
February 06, 2023 Filed Feb 8, 2023 21:49 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	5,959	$27.64	$164,697.23	Disclosure SEC source: 0001562180-23-001118 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 735,987 options to purchase shares of common stock that are vested and immediately exercisable and a total of 809,583 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $27.50 to $27.84. Read SEC document
February 06, 2023 Filed Feb 8, 2023 21:49 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	5,959	$6.38	$38,018.42	Disclosure SEC source: 0001562180-23-001118 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:02 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Options (Right to buy) · Derivative	410,000	$28.55 Strike: $28.55	$11,705,500.00	Disclosure SEC source: 0001562180-23-000956 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	63,000	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · derivative · entry 7 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2030-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying the option were fully vested on March 11, 2021, the date that is twelve months after the date of grant. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	28,500	$0.00 Strike: $0.84	$0.00	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,500 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Salecommon stock	4,500	$5.70	$25,659.90	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · nonDerivative · entry 5 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.70 to $ 5.72. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Salecommon stock	36,942	$5.65	$208,578.23	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.60 to $ 5.695. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Salecommon stock	50,058	$5.53	$276,780.69	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,442 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.50 to $ 5.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Exercise / conversioncommon stock	63,000	$1.00	$63,000.00	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 08, 2022 Filed Nov 10, 2022 16:54 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Exercise / conversioncommon stock	28,500	$0.84	$23,971.35	Disclosure SEC source: 0000891293-22-000055 · primary_doc.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 06, 2022 Filed Oct 7, 2022 20:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	16,231	$0.00 Strike: $8.77	$0.00	Disclosure SEC source: 0001562180-22-007124 · primarydocument.xml · derivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,231 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
October 06, 2022 Filed Oct 7, 2022 20:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	16,231	$25.29	$410,507.96	Disclosure SEC source: 0001562180-22-007124 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 674,528 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $25.1500 to $25.4350. Read SEC document
October 06, 2022 Filed Oct 7, 2022 20:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	16,231	$8.77	$142,345.87	Disclosure SEC source: 0001562180-22-007124 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 04, 2022 Filed Oct 4, 2022 21:49 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	1,280	$0.00 Strike: $8.77	$0.00	Disclosure SEC source: 0001562180-22-007012 · primarydocument.xml · derivative · entry 9 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.